Private Funds
Palogic manages two private pooled funds—the Palogic Master Fund and the Palogic Offshore Fund—as general partner and investment advisor.
palogicfund.comCrawled Oct 30, 2026
Palogic manages two private pooled funds—the Palogic Master Fund and the Palogic Offshore Fund—as general partner and investment advisor.
Palogic creates personalized financial plans covering retirement, taxes, healthcare, and estate planning, adjusting as client needs evolve.
The Principals have collaborated since 2009 to identify long-term value in the small-cap market segment.
Contact Palogic by filling out the form on this page and a team member will be in touch. Headquartered in Dallas, Texas.
Palogic offers investment management for two private pooled funds and personalized wealth management plans.
Palogic Value Management acquires a **7.1% activist stake** in **Health Catalyst (NASDAQ: HCAT)**, a healthcare technology company specializing in data-driven clinical and financial performance solutions. The move signals potential pressure for strategic changes or governance reforms. Health Catalyst serves hospitals and health systems, offering analytics platforms to improve patient outcomes and operational efficiency.
Palogic Value Fund raises concerns to Granite Point Mortgage Trust’s board over its weakened market position, worsening credit quality, shrinking profit margins, and inefficient cost structure. The fund highlights operational and financial challenges that may undermine the company’s long-term stability. The letter targets strategic and fiscal issues as key areas of risk for investors.
Palogic expresses significant concerns over Pebblebrook Hotel Trust’s ability to grow net asset value. The firm advises the board to consider selling the entire company. No details on financial performance or alternative strategies are provided.
Palogic Value Fund removes its director nominees and shareholder proposal from Pebblebrook Hotel Trust. The move follows ongoing disputes over net asset value (NAV) growth, executive accountability, and misalignment with shareholder interests. The fund cites persistent concerns about governance and financial performance as key factors in its decision.
ReCode Therapeutics secures an additional **$120 million** in its Series B funding round, expanding its biopharma development efforts in Dallas. The company, focused on RNA-based therapies, joins a wave of North Texas health-care and tech investments. Meanwhile, Enhabit Home Health completes its NYSE listing, while Irving-based Web3 investor launches two new funds targeting decentralized finance and infrastructure.
Palogic Value Management, LP sends an open letter to SPOK Holdings, Inc. as a shareholder holding approximately 800,000 shares (4.3% of outstanding stock). The firm addresses the company’s board of directors ahead of the March 24, 2020 market close. The letter reflects concerns or recommendations related to SPOK’s operations or governance, though specifics are not disclosed in the announcement.